An observational study in Liver Cirrhosis and Gastrointestinal Bleeding, sponsored by St. Martin De Porress Hospital. Recruiting at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by St. Martin De Porress Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Liver Cirrhosis with a site in Taiwan — 6 open to participants now, 7 under way, 1 of them phase 3. Liver Cirrhosis · Taiwan.
Among the 35 studies in Liver Cirrhosis with a site in Taiwan, this one is the 11th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, and was the 32nd registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →6 of the 35 studies in Liver Cirrhosis with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 18–80
Boehringer Ingelheim · Sites in Taiwan, United States, Argentina and 34 more countries
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
European Foundation for Study of Chronic Liver Failure · Sites in Taiwan, United States, Argentina and 24 more countries
Ages 18–80
Gwo Xi Stem Cell Applied Technology Co., Ltd. · Sites in Taiwan
Ages 20–70
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 60 across the 21 interventional studies, 200 across the 14 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 35 have an industry lead sponsor. The 10 most frequent:
St. Martin De Porress Hospital is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
St. Martin De Porress Hospital has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Cirrhosis with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT06680583St. Martin De Porress HospitalUtilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding | 2027-03-11 |
| NCT07400367Fu Jen Catholic University HospitalImpact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Liver Cirrhosis with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the prognosis of cirrhosis patients with gastrointestinal bleeding? To explore the improvement of emergency and critical care patient management.
Cirrhosis is a common chronic liver disease with gastrointestinal bleeding being one of its complications. Gastrointestinal bleeding is quite common in patients with cirrhosis, but its prognosis is difficult to accurately predict. In current clinical practice, critical care physicians often use physiological indicators to assess the risk level of patients. Among them, the Shock Index and its derived indicators such as the Modified Shock Index, Age Shock Index, and Respiratory Adjusted Shock Index have been widely used in other fields, but their actual value in patients with cirrhosis complicated by gastrointestinal bleeding is not yet clear.
The prognosis of cirrhosis patients with gastrointestinal bleeding affects the quality of life and survival of the patients, thus necessitating the establishment of a reliable prognostic assessment tool to assist critical care physicians in making rapid treatment decisions. The motivation of this study is to explore the application value of Shock Index-related indicators in predicting the prognosis of cirrhosis patients with gastrointestinal bleeding, in order to improve the medical efficiency for this specific group of critically ill patients.
cirrhosis with gastrointestinal bleeding
Inclusion Criteria: cirrhosis with gastrointestinal bleeding -
Exclusion Criteria: no complete medical record and trauma patient
-
cirrhosis with gastrointestinal bleeding
Other: physical indicators such as shock index relatives
shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding
Also known as: MSI, Age SI, RASI
shock index= heart rate / systolic blood pressure normal range:0.5-0.7 Modified shock index = heart rate/mean arterial pressure(MAP) age shock index = SI x age number respiratory adjusted shock index(RASI) = HR/SBP × RR/10. MAP = DP + 1/3(SP - DP)
find the shock index relatives indicators in the prognosis prediction of cirrhosis with gastrointestinal bleeding
Time frame: through study completion, an average of 6 months
Plan to share: No — This study include the medical privacy of cirrhosis.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Martin De Porress Hospital